Showing 31-40 of 48 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Sparing ER stressed human beta cells with novel kinase inhibitors of the unfolded protein response (UPR) | The Regents of the University of California, San Francisco | Feroz Papa | Cures | 01-August-2023 to 31-July-2026 | $960.000,00 |
| Non-invasive immunoimaging of islet transplant rejection | Beckman Research Institute of the City of Hope | Fouad Kandeel | Cures | 01-June-2023 to 31-May-2026 | $750.000,00 |
| Cellular Sentinels of Islet Transplant Rejection | California Institute of Technology | Mikhail Shapiro | Cures | 01-July-2023 to 30-June-2026 | $750.000,00 |
| Multiplex in vivo imaging of the dynamics of immune-mediated rejection of allogenic islet grafts | The Regents of the University of California, Los Angeles | Oluwatayo Ikotun | Cures | 01-February-2024 to 31-January-2027 | $749.996,25 |
| Reducing Diabetes Distress in Adults with Type 1 Diabetes: A pragmatic trial in routine diabetes care. | The Regents of the University of California, San Francisco | Danielle Hessler | Improving Lives | 01-August-2023 to 31-July-2026 | $1.743.010,00 |
| Novel insulin formulations for pumps | Stanford University | Yanxian Zhang | Improving Lives | 01-March-2023 to 28-February-2026 | $243.986,00 |
| Development of Low Cost, High Precision Nano Pumps for Insulin Delivery | Torramics Inc. | Sergey Gimelshein | Improving Lives | 01-March-2023 to 31-August-2026 | $1.493.212,43 |
| Development of a Microfluidic Patch Pump for Next-Generation Wearable Artificial Pancreas Systems | University of California, Santa Barbara | Sumita Pennathur | Improving Lives | 01-May-2023 to 30-April-2026 | $1.065.254,36 |
| Real time monitoring of a cell therapy product to assess and modify transplant health post-engraftment in patients with type 1 diabetes | Minutia | Katy Digovich | Cures | 01-November-2022 to 31-March-2026 | $1.198.600,00 |
| Acetazolamide and Tubuloglomerular Feedback in Persons with Type 1 Diabetes: A Clinical Trial | University of California, San Diego | Charles Ginsberg | Improving Lives | 01-November-2022 to 31-October-2026 | $1.356.726,45 |